AbbVie earnings beat by $0.08, revenue topped estimates

Investing.com – AbbVie (NYSE: ) reported third quarter EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93B versus the consensus estimate of $13.71B.

Guidance

AbbVie sees Q4 2023 EPS of $11.19-$11.23 versus the analyst consensus of $11.06.

AbbVie’s stock price closed at $145.20. It is down -3.75% in the last 3 months and down -1.63% in the last 12 months.

AbbVie saw 10 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See AbbVie’s stock price’s past reactions to earnings here.

According to InvestingPro, AbbVie’s Financial Health score is “great performance”.

Check out AbbVie’s , and AbbVie’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar